Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal and in vitro laboratory research
PubMed 32661391 · doi:10.1038/s41591-020-0945-x
What was done
The authors evaluated the role of the GDF15-GFRAL-RET signaling pathway in cancer-associated cachexia. They generated 3P10, an antagonistic monoclonal antibody targeting GFRAL that blocks the interaction between GDF15, GFRAL, and RET. The antibody was tested in tumor-bearing mice, including under calorie-restricted conditions. Mechanisms driving adipose tissue wasting were assessed using mouse models with peripheral chemical sympathectomy and genetic deficiency of adipose triglyceride lipase.
What was found
The abstract reports qualitative findings without numerical values or effect sizes. Treatment with 3P10 inhibited RET signaling and reversed excessive lipid oxidation and cachexia in tumor-bearing mice, even under calorie restriction. GFRAL-RET pathway activation induced adipose lipid metabolism gene expression. Both peripheral chemical sympathectomy and loss of adipose triglyceride lipase protected mice from GDF15-induced weight loss, indicating that GDF15 drives adipose lipolysis through a peripheral sympathetic axis independent of anorexia.
Why it matters
This study identifies a peripheral sympathetic mechanism driving adipose wasting via GDF15-GFRAL signaling and suggests that blocking GFRAL could be a viable therapeutic strategy for cancer cachexia.
Limits
This is preclinical animal and bench research with no human subjects. The abstract provides no quantitative data, sample sizes, tumor model specifics, dosage information, or statistical confidence intervals.
Cited by
- supports Cancer patients who develop cachexia exhibit elevated circulating levels of GDF15.